CPI-613: Phase I started

Cornerstone began an open-label, dose-escalation, U.S. Phase I trial to evaluate IV CPI-613 in combination with Treanda bendamustine and Rituxan/ MabThera rituximab in 4-week cycles for up to 6 cycl...